Citigroup’s Adverum Biotechnologies ADVM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-14,752
| Closed | -$64.5K | – | 5628 |
|
|
2025
Q1 | $64.5K | Sell |
14,752
-5,235
| -26% | -$23.6K | ﹤0.01% | 4804 |
|
|
2024
Q4 | $93.3K | Buy |
19,987
+4,839
| +32% | +$32.6K | ﹤0.01% | 4873 |
|
|
2024
Q3 | $106K | Buy |
15,148
+10,479
| +224% | +$76.1K | ﹤0.01% | 4740 |
|
|
2024
Q2 | $32K | Sell |
4,669
-47,936
| -91% | -$446K | ﹤0.01% | 4826 |
|
|
2024
Q1 | $744K | Buy |
+52,605
| New | +$800K | ﹤0.01% | 3262 |
|
|
2023
Q4 | – | Sell |
-47,669
| Closed | -$715K | – | 5679 |
|
|
2023
Q3 | $715K | Buy |
+47,669
| New | +$856K | ﹤0.01% | 2783 |
|
|
2022
Q4 | – | Sell |
-119
| Closed | -$1K | – | 5755 |
|
|
2022
Q3 | $1K | Sell |
119
-122
| -51% | -$1.6K | ﹤0.01% | 5599 |
|
|
2022
Q2 | $3K | Sell |
241
-354
| -59% | -$3.71K | ﹤0.01% | 5757 |
|
|
2022
Q1 | $8K | Sell |
595
-1,950
| -77% | -$28.5K | ﹤0.01% | 5621 |
|
|
2021
Q4 | $45K | Sell |
2,545
-4,397
| -63% | -$88K | ﹤0.01% | 5111 |
|
|
2021
Q3 | $151K | Sell |
6,942
-67,406
| -91% | -$1.72M | ﹤0.01% | 4244 |
|
|
2021
Q2 | $2.6M | Buy |
74,348
+41,295
| +125% | +$2.22M | ﹤0.01% | 2456 |
|
|
2021
Q1 | $3.26M | Buy |
33,053
+29,499
| +830% | +$3.54M | ﹤0.01% | 2129 |
|
|
2020
Q4 | $385K | Sell |
3,554
-18,709
| -84% | -$2.31M | ﹤0.01% | 4435 |
|
|
2020
Q3 | $2.29M | Sell |
22,263
-28,304
| -56% | -$4.24M | ﹤0.01% | 2533 |
|
|
2020
Q2 | $10.6M | Buy |
50,567
+43,171
| +584% | +$7.65M | 0.01% | 1254 |
|
|
2020
Q1 | $723K | Buy |
7,396
+4,003
| +118% | +$467K | ﹤0.01% | 3514 |
|
|
2019
Q4 | $391K | Sell |
3,393
-15,826
| -82% | -$1.39M | ﹤0.01% | 4640 |
|
|
2019
Q3 | $1.05M | Buy |
19,219
+13,234
| +221% | +$1.49M | ﹤0.01% | 3599 |
|
|
2019
Q2 | $711K | Buy |
5,985
+4,539
| +314% | +$376K | ﹤0.01% | 4046 |
|
|
2019
Q1 | $75K | Buy |
1,446
+114
| +9% | +$4.61K | ﹤0.01% | 5999 |
|
|
2018
Q4 | $42K | Sell |
1,332
-163
| -11% | -$6.63K | ﹤0.01% | 6370 |
|
|
2018
Q3 | $90K | Buy |
1,495
+428
| +40% | +$24K | ﹤0.01% | 6006 |
|
|
2018
Q2 | $57K | Buy |
+1,067
| New | +$64.2K | ﹤0.01% | 6175 |
|
|
2017
Q2 | – | Sell |
-228
| Closed | -$6K | – | 7322 |
|
|
2017
Q1 | $6K | Sell |
228
-2,287
| -91% | -$65K | ﹤0.01% | 6727 |
|
|
2016
Q4 | $73K | Buy |
2,515
+1,443
| +135% | +$47.2K | ﹤0.01% | 5963 |
|
|
2016
Q3 | $44K | Buy |
1,072
+133
| +14% | +$5.04K | ﹤0.01% | 5738 |
|
|
2016
Q2 | $30K | Sell |
939
-1,193
| -56% | -$53.9K | ﹤0.01% | 5886 |
|
|
2016
Q1 | $110K | Buy |
2,132
+1,340
| +169% | +$74.8K | ﹤0.01% | 5597 |
|
|
2015
Q4 | $75K | Buy |
792
+594
| +300% | +$52.2K | ﹤0.01% | 5604 |
|
|
2015
Q3 | $16K | Sell |
198
-7,337
| -97% | -$937K | ﹤0.01% | 6166 |
|
|
2015
Q2 | $1.22M | Buy |
7,535
+5,982
| +385% | +$2.02M | ﹤0.01% | 2999 |
|
|
2015
Q1 | $629K | Buy |
1,553
+947
| +156% | +$400K | ﹤0.01% | 3527 |
|
|
2014
Q4 | $328K | Buy |
606
+554
| +1,065% | +$214K | ﹤0.01% | 4264 |
|
|
2014
Q3 | $18K | Buy |
+52
| New | +$15.5K | ﹤0.01% | 5962 |
|
Other funds holding ADVM
BCM
PWA
TCM
FLSM
5VM
VVM
Citigroup's ADVM Position: Q2 2025 in Review
Citigroup sold out of Adverum Biotechnologies (ADVM) in Q2 2025, closing a stake of 14,752 shares — an estimated $64.5K sold.
Citigroup first reported a position in ADVM in Q3 2014 and held it in 35 quarters. The position peaked at $10.6M in Q2 2020. 58 funds tracked by Wall St. Rank hold ADVM as of Q2 2025.
- Citigroup reported no remaining Adverum Biotechnologies position as of Q2 2025 after selling out during the quarter.
- Citigroup sold 14,752 Adverum Biotechnologies shares in Q2 2025, an estimated $64.5K.
- Citigroup first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 35 quarters.
- Citigroup's Adverum Biotechnologies position peaked at $10.6M in Q2 2020.
- 58 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2025.
Based on Citigroup's 13F filing for Q2 2025, filed 11 Aug 2025.